Global Pandemic Conditions and List of Possible Medications and Vaccines for the Treatment of COVID-19: A Review
Article Sidebar
Submitted
11 May 2020
Published
22 June 2020
Keywords:
-
Chloroquine, China, COVID-19, Lopinavir, SARS-CoV-2, Teicoplanin
Abstract
At the end of December 2019, a novel coronavirus was identified which caused severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with a disease known as coronavirus disease 2019 (COVID-19). The virus first originated in the city of Wuhan in China, causing symptoms such as pneumonic plague, which began in the Wuhan and then spread throughout the world with high transmission efficiency. Special precautions and care are needed such as leaving the public area, covering your mouth with a mask, not shaking hands, washing hands, and sanitation from time to time. Infection due to SARS-CoV-2 shows several symptoms, one of which is very often the patient shows difficulty breathing. Currently, COVID-19 has been declared a global pandemic and has almost attacked all countries in the world, including in India which has one of the largest human populations in the entire world. One of the challenges in handling COVID-19 is the unavailability of drugs or special vaccines to treat the disease, so clinical practitioners and academics are currently testing various drugs to see how they affect the COVID-19 patients. Some of the drugs tested provide effective mechanisms against SARS-CoV-2, such as chloroquine, remdesivir, lopinavir, and vaccines under development. These drugs are still being tested and are now at the forefront to combat the effects of SARS-CoV-2 infection. This review article will discuss all kinds of ins and outs of SARS-CoV-2 and COVID-19, including the transmission method, how to prevent it, as well as various drugs and vaccines currently used in handling COVID-19.
Full text article
Generated from XML file
References
Algernon Pharmaceuticals. (2020). NP-120 (Ifenprodil). https://algernonpharmaceuticals.com/ipf-np-120/
Ali, I. & Alharbi, O.M.L. (2020). COVID-19: Disease, management, treatment, and social impact. The Science of The Total Environment, 728, 138861. doi:10.1016/j.scitotenv.2020.138861
APEIRON Biologics. (2020). APEIRON Biologics closes oversubscribed financing round of EUR 17.5 million for the development of APN01 against COVID-19. https://www.apeiron-biologics.com/wp-content/uploads/2020/06/200602_APEIRON_Closing-Financing_ENG_final.pdf
Astuti, I. & Ysrafil. (2020). Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. Diabetes and Metabolic Syndrome, [Epub ahead of print]. doi:10.1016/j.dsx.2020.04.020
Baron, S.A., Devaux, C., Colson, P., Raoult, D., & Rolain, J.M. (2020). Teicoplanin: An Alternative Drug for the Treatment of COVID-19? International Journal of Antimicrobial Agents, 55(4), 105944. doi:10.1016/j.ijantimicag.2020.105944
BeyondSpring. (2020). BeyondSpring Files for Patent Protection on BPI-002 for the Treatment of Viral Infections Including COVID-19. https://www.beyondspringpharma.com/pressreleases/info.aspx?itemid=2212
Biocryst Pharmaceuticals. (2020). Galidesivir. https://www.biocryst.com/our-program/galidesivir/
Bioxytran. (2020). Bioxytran Seeking Partners for Late Stage Treatment of Wuhan Coronavirus using BXT-25. https://www.bioxytraninc.com/press-releases/bioxytran-seeking-partners-for-late-stage-treatment-of-wuhan-coronavirus-using-bxt-25
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., Li X., Xia, J., Chen, N., Xiang, J., Yu, T., Bai, T., Xie, X., Zhang, L., Li, C., Yuan, Y., Chen, H., Li, H., Huang, H., Tu, S., Gong, F., Liu, Y., Wei, Y., Dong, C., Zhou, F., Gu, X., Xu, J., Liu, Z., Zhang, Y., Li, H., Shang, L., Wang, K., Li, K., Zhou, X., Dong, X., Qu, Z., Lu, S., Hu, X., Ruan, S., Luo, S., Wu, J., Peng, L., Cheng, F., Pan, L., Zou, J., Jia, C., Wang, J., Liu, X., Wang, S., Wu, X., Ge, Q., He, J., Zhan, H., Qiu, F., Guo, L., Huang, C., Jaki, T., Hayden, F.G., Horby, P.W., Zhang, D., & Wang, C. (2020). A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. The New England Journal of Medicine, 382, 1787-1799. doi:10.1056/NEJMoa2001282
Cui, J., Li, F., & Shi, Z.L. (2019). Origin and evolution of pathogenic coronaviruses. Nature Reviews Microbiology, 17(3), 181-192. doi:10.1038/s41579-018-0118-9
Djalante, R., Lassa, J., Setiamarga, D., Sudjatma, A., Indrawan, M., Haryanti, B., Mahfud, C., Sinapoy, M.S., Djalante, S., Rafliana, I., Gunawan, L.A., Surtiari, G.A.K., & Warsilah, H. (2020). Review and analysis of current responses to COVID-19 in Indonesia: Period of January to March 2020. Progress in Disaster Science, 6, 10091. doi:10.1016/j.pdisas.2020.100091
Doremalen, N.V., Lambe, T., Spencer, A., Belji-Rammerstorfer, S., Purusthotham, J.N., Port, J.R., Avanzato, V., Bushmaker, T., Flaxman, A., Ulaszewska, M., Feldmann, F., Allen, E.R., Sharpe, H., Schulz, J., Holbrook, M., Okumura, A., Meade-White, K., Perez-Perez, L., Bissett, C., Gilbride, C., Williamson, B.N., Rosenke, R., Long, D., Ishwarbhai, A., Kailath, R., Rose, L., Morris, S., Powers, C., Lovaglio, J., Hanley, P.W., Scott, D., Saturday, G., de Wit, E., Gilbert, S.C., & Munster, V.J. (2020). ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. BioRXiv. Preprint, 093195. doi:10.1101/2020.05.13.093195
Duddu, P. (2020). Coronavirus treatment: Vaccines/drugs in the pipeline for COVID-19. https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/
El-Aziz, T.M.A. & Stockand, J.D. (2020). Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status. Infection, Genetics and Evolution, 104327. doi:10.1016/j.meegid.2020.104327
Gautret, P., Lagier, J.C., Parola, P., Hoang, V.T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V.E., Dupont, H.T., Honore, S., Colson, P., Chabriere, E., La Scola, B., Rolain, J.M., Brouqui, P., & Raoult, D. (2020). Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Results of an Open-Label Non-Randomized Clinical Trial. International Journal of Antimicrobial Agents, 105949. doi:10.1016/j.ijantimicag.2020.105949
Guner, R., Hasanoglu, I., & Aktas, F. (2020). COVID-19: Prevention and control measures in community. Turkish Journal of Medical Sciences, 50(3), 571-577. doi:10.3906/sag-2004-146
Guo, Y.R., Cao, Q.D., Hong, Z.S., Tan, Y.Y., Chen S.D., Jin, H.J., Tan, K.S., Wang, D.Y., & Yan, Y. (2020). The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Military Medical Research, 7, 11. doi:10.1186/s40779-020-00240-0
Indian Council of Medical Research. (2020). Total Operational (initiated independent testing) Laboratories reporting to ICMR. https://www.icmr.gov.in/pdf/covid/labs/COVID_19_Testing_Labs_06052020.pdf
Innovation Pharmaceuticals. (2020). Brilacidin. http://www.ipharminc.com/brilacidin-1
Khan, S., Siddique, R., Shereen, M.A., Ali, A., Liu, J., Bai, Q., Bashir, N., & Xue, M. (2020a). Emergence of a Novel Coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2: Biology and Therapeutic Options. Journal of Clinical Microbiology, 58(5), 00187-20. doi:10.1128/JCM.00187-20
Khan, S., Nabi, G., Han, G., Siddique, R., Lian, S., Shi, H., Bashir, N., Ali, A., & Shereen, M.A. (2020b). Novel coronavirus: how things are in Wuhan. Clinical Microbiology and Infection, 26(4), 399-400. doi:10.1016/j.cmi.2020.02.005
Lauer, S.A., Grantz, K.H., Bi, Q., Jones, F.K., Zheng, Q., Meredith, H.R., Azman, A.S., Reich, N.G., & Lessler, J. (2020). The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Annals of Internal Medicine, 172(9), 577-582. doi:10.7326/m20-0504
Li, H., Liu, S.M., Yu, X.H., Tang, S.L., & Tang, C.K. (2020). Coronavirus disease 2019 (COVID-19): current status and future perspectives. International Journal of Antimicrobial Agents, 105951. doi:10.1016/j.ijantimicag.2020.105951
Liu, J., Liao, X., Qian, S., Yuan, J., Wang, F., Liu, Y., Wang, Z., Wang, F.S., Liu, L., & Zhang, Z. (2020a). Community Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, Shenzhen, China, 2020. Emerging Infectius Diseases, 26(6), [Epub ahead of print]. doi:10.3201/eid2606.200239
Liu, J., Cao, R., Xu, M., Wang, X., Zhang, H., Hu, H., Li, Y., Hu, Z., Zhong, W., & Wang, M. (2020b). Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery, 6, 16. doi:10.1038/s41421-020-0156-0
Magro, G. (2020). SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the ‘culprit lesion’ of ARDS onset? What is there besides Tocilizumab? SGP130Fc. Cytokine: X, 2(2), 100029. doi:10.1016/j.cytox.2020.100029
Mantlo, E., Bukreyeva, N., Maruyama, J., Paessler, S., & Huang, C. (2020). Antiviral activities of type I interferons to SARS-CoV-2 infection. Antiviral Research, 179, 104811. doi:10.1016/j.antiviral.2020.104811
Megarbane, B. (2020). Chloroquine and hydroxychloroquine to treat COVID-19: between hope and caution. Clinical Toxicology, 1080(10), 1-3. doi:10.1080/15563650.2020.1748194
Mensa, B., Howell, G.L., Scott, R., & DeGrado, W.F. (2014). Comparative Mechanistic Studies of Brilacidin, Daptomycin, and the Antimicrobial Peptide LL16. Antimicrobial Agents and Chemotherapy, 58(9), 5136-5145. doi:10.1128/AAC.02955-14
Moderna. (2020). Moderna Advances Late-Stage Development of its Vaccine (mRNA-1273) Against COVID-19. https://investors.modernatx.com/news-releases/news-release-details/moderna-advances-late-stage-development-its-vaccine-mrna-1273
Morawska, L. & Cao, J. (2020). Airborne transmission of SARS-CoV-2: the world should face the reality. Environment International, 105730. doi:10.1016/j.envint.2020.105730
Norrie, J.D. (2020). Remdesivir for COVID-19: challenges of underpowered studies. The Lancet, 395(10236), 1525-1527. doi:10.1016/S0140-6736(20)31023-0
Omer, S., Ali, S., & Babar, Z.D. (2020). Preventive measures and management of COVID-19 in pregnancy. Drugs and Therapy Perspectives, 1-4. doi:10.1007/s40267-020-00725-x
Pal, M., Berhanu, G., Desalegn, C., & Kandi, V. (2020). Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update. Cureus, 12(3), e7423. doi:10.7759/cureus.7423
Pawar, A.Y. (2020). Combating Devastating COVID -19 by Drug Repurposing. International Journal if Antimicrobial Agents, 105984. doi:10.1016/j.ijantimicag.2020.105984
Peng, X., Xu, X., Li, Y., Cheng, L., Zhou, X., & Ren, B. (2020). Transmission routes of 2019-nCoV and controls in dental practice. International Journal of Oral Science, 12, 9. doi:10.1038/s41368-020-0075-9
Regeneron Pharmaceuticals. (2020). Corporate Overview. https://investor.regeneron.com/static-files/c1be21c5-bd18-45e4-b8ba-e09e3755fdf5
Rockx, B., Kuiken, T., Herfst, S., Bestebroer, T., Lamers, M.M., Munnink, B.B.O., de Meulder, D., van Amerongen, G., van den Brand, J., Okba, N.M.A., Schipper, D., van Run, P., Leitjen, L., Sikkema, R., Verschoor, E., Verstrepen, B., Bogers, W., Langermans, J., Drosten, C., van Vlissingen, M.F., Fouchier, R., de Swart, R., Koopmans, M., & Haagmans, B.L. (2020). Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science, eabb7314. doi:10.1126/science.abb7314
Sandra, R. (2020). Airway Therapeutics Announces Filing with NIH To Evaluate AT-100 as a Therapy for Novel Coronavirus. https://www.airwaytherapeutics.com/airway-therapeutics-announces-filing-with-nih-to-evaluate-at-100-as-a-therapy-for-novel-coronavirus/
Seah, I., Su, X., & Lingam, G. (2020). Revisiting the dangers of the coronavirus in the ophthalmology practice. Eye, [Epub ahead of print]. doi:10.1038/s41433-020-0790-7
Singhal, T. (2020). A Review of Coronavirus Disease-2019 (COVID-19). Indian Journal of Pediatrics, 8(4), 281-286. doi:10.1007/s12098-020-03263-6
Synairgen Research. (2020). Synairgen to start trial of SNG001 in COVID-19 imminently. https://www.synairgen.com/wp-content/uploads/2020/03/200318-Synairgen-to-start-trial-of-SNG001-in-COVID-19-imminently-.pdf
Takeda. (2020). Rajeev Venkayya, President, Global Vaccine Business Unit on the latest on the Coronavirus and Takeda. https://www.takeda.com/newsroom/featured-topics/rajeev-venkayya-president-global-vaccine-business-unit-on-the-latest-on-the-coronavirus-and-takeda/
Tay, M.Z., Poh, C.M., Renia, L., MacAry, P.A., & Ng, L.F.P. (2020). The trinity of COVID-19: immunity, inflammation and intervention. Nature Reviews Immunology, 1-12. doi:10.1038/s41577-020-0311-8
Tiziana Life Sciences. (2020). Tiziana Lifesciences Develops Novel Investigational Treatment for Patients Infected with COVID-19 Utilizing Direct Delivery of Anti-Interlukin-6-Receptor Monoclonal Antibodies. https://www.globenewswire.com/news-release/2020/04/09/2014044/0/en/Tiziana-Lifesciences-Develops-Novel-Investigational-Treatment-For-Patients-Infected-with-COVID-19-Utilizing-Direct-Delivery-of-Anti-Interlukin-6-Receptor-Monoclonal-Antibodies.html
Tonix Pharmaceuticals. (2020). TNX-1800 (Coronavirus Vaccine). https://www.tonixpharma.com/pipeline/tnx-1800-coronavirus-vaccine
Walls, A.C., Park, Y.J., Tortorici, M.A., Wall, A., McGuire, A.T., & Veesler, D. (2020). Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell, 181(2), 281-292. doi:10.1016/j.cell.2020.02.058
Wang, Q., Zhang, Y., Wu, L., Niu, S., Song, C., Zhang, Z., Lu, G., Qiao, C., Hu, Y., Yuen, K.Y., Wang, Q., Zhou, H., Yang, J., & Qi, J. (2020a). Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell, [Epub ahead of print]. doi:10.1016/j.cell.2020.03.045
Wang, S.X., Wang, Y., Lu, Y.B., Li, J.Y., Song, Y.J., Nyamgerelt, M., & Wang, X.X. (2020b). Diagnosis and treatment of novel coronavirus pneumonia based on the theory of traditional Chinese medicine. Journal of Integrative Medicine, [Epub ahead of print]. doi:10.1016/j.joim.2020.04.001
Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., Hu, Y., Luo, G., Wang, K., Lu, Y., Li, H., Wang, S., Ruan, S., Yang, C., Mei, C., Wang, Y., Ding, D., Wu, F., Tang, X., Ye, X., Ye, Y., Liu, B., Yang, J., Yin, W., Wang, A., Fan, G., Zhou, F., Liu, Z., Gu, X., Xu, J., Shang, L., Zhang, Y., Cao, L., Guo, T., Wan, Y., Qin, H., Jiang, Y., Jaki, T., Hayden, F.G., Horby, P.W., Cao, B., & Wang, C. (2020c). Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet, 395(10236), 1569-1578. doi:10.1016/S0140-6736(20)31022-9
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020d). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research, 30, 269-271. doi:10.1038/s41422-020-0282-0
de Wit, E., Feldmann, F., Okumura, A., Horne, E., Haddock, E., Saturday, G., Scott, D., Erlandson, K.J., Stahl, N., Lipsich, L., Kyratsous, C.A., & Feldmann, H. (2018). Prophylactic and Therapeutic Efficacy of mAb Treatment Against MERS-CoV in Common Marmosets. Antiviral Research, 156, 64-71. doi:10.1016/j.antiviral.2018.06.006
World Health Organization. (2020). DRAFT landscape of COVID-19 candidate vaccines–20 April 2020. https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1
Worldometer. (2020). COVID-19 Coronavirus Pandemic. https://www.worldometers.info/coronavirus/
Xu, J., Zhao, S., Teng, T., Abdalla, A.E., Zhu, W., Xie, L., Wang, Y., & Guo, X. (2020). Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV. Viruses, 12(2), 244. doi:10.3390/v12020244
Yi, Y., Lagniton, P.N.P., Ye, S., Li, E., & Xu, R.H. (2020). COVID-19: what has been learned and to be learned about the novel coronavirus disease. International Journal of Biological Sciences, 16(10), 1753-1766. doi:10.7150/ijbs.45134
Yuen, K.S., Ye, Z.W., Fung, S.Y., Chan, C.P., & Jin, D.Y. (2020). SARS-CoV-2 and COVID-19: The most important research questions. Cell and Bioscience, 10, 40. doi:10.1186/s13578-020-00404-4
Zhai, P., Ding, Y., Wu, X., Long, J., Zhong, Y., & Li, Y. (2020). The epidemiology, diagnosis and treatment of COVID-19. International Journal of Antimicrobial Agents, 105955. doi:10.1016/j.ijantimicag.2020.105955
Zhang, H., Penninger, J.M., Li, Y., Zhong, N., & Slusky, A.S. (2020). Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Medicine, 46(4), 586-590. doi:10.1007/s00134-020-05985-9
Zhou, P., Yang, X., Wang, X. Hu, B., Zhang, L., Zhang, W., Si, H.R., Zhu, Y., Li, B., Huang, C.L., Chen, H.D., Chen, J., Luo, Y., Guo, H., Jiang, R.D., Liu, M.Q., Chen, Y., Shen, X.R., Wang, X., Zheng, X.S., Zhao, K., Chen, Q.J., Deng, F., Liu, L.L., Yan, B., Zhan, F.X., Wang, Y.Y., Xiao, G.F., & Shi., Z.L. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579(7798), 270–273. doi:10.1038/s41586-020-2012-7
Zumla, A., Chan, J.F., Azhar, E.I., Hui, D.S., & Yuen, K.Y. (2016). Coronaviruses - drug discovery and therapeutic options. Nature Reviews Drug Discovery, 15(5), 327-347. doi:10.1038/nrd.2015.37
Ali, I. & Alharbi, O.M.L. (2020). COVID-19: Disease, management, treatment, and social impact. The Science of The Total Environment, 728, 138861. doi:10.1016/j.scitotenv.2020.138861
APEIRON Biologics. (2020). APEIRON Biologics closes oversubscribed financing round of EUR 17.5 million for the development of APN01 against COVID-19. https://www.apeiron-biologics.com/wp-content/uploads/2020/06/200602_APEIRON_Closing-Financing_ENG_final.pdf
Astuti, I. & Ysrafil. (2020). Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. Diabetes and Metabolic Syndrome, [Epub ahead of print]. doi:10.1016/j.dsx.2020.04.020
Baron, S.A., Devaux, C., Colson, P., Raoult, D., & Rolain, J.M. (2020). Teicoplanin: An Alternative Drug for the Treatment of COVID-19? International Journal of Antimicrobial Agents, 55(4), 105944. doi:10.1016/j.ijantimicag.2020.105944
BeyondSpring. (2020). BeyondSpring Files for Patent Protection on BPI-002 for the Treatment of Viral Infections Including COVID-19. https://www.beyondspringpharma.com/pressreleases/info.aspx?itemid=2212
Biocryst Pharmaceuticals. (2020). Galidesivir. https://www.biocryst.com/our-program/galidesivir/
Bioxytran. (2020). Bioxytran Seeking Partners for Late Stage Treatment of Wuhan Coronavirus using BXT-25. https://www.bioxytraninc.com/press-releases/bioxytran-seeking-partners-for-late-stage-treatment-of-wuhan-coronavirus-using-bxt-25
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., Li X., Xia, J., Chen, N., Xiang, J., Yu, T., Bai, T., Xie, X., Zhang, L., Li, C., Yuan, Y., Chen, H., Li, H., Huang, H., Tu, S., Gong, F., Liu, Y., Wei, Y., Dong, C., Zhou, F., Gu, X., Xu, J., Liu, Z., Zhang, Y., Li, H., Shang, L., Wang, K., Li, K., Zhou, X., Dong, X., Qu, Z., Lu, S., Hu, X., Ruan, S., Luo, S., Wu, J., Peng, L., Cheng, F., Pan, L., Zou, J., Jia, C., Wang, J., Liu, X., Wang, S., Wu, X., Ge, Q., He, J., Zhan, H., Qiu, F., Guo, L., Huang, C., Jaki, T., Hayden, F.G., Horby, P.W., Zhang, D., & Wang, C. (2020). A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. The New England Journal of Medicine, 382, 1787-1799. doi:10.1056/NEJMoa2001282
Cui, J., Li, F., & Shi, Z.L. (2019). Origin and evolution of pathogenic coronaviruses. Nature Reviews Microbiology, 17(3), 181-192. doi:10.1038/s41579-018-0118-9
Djalante, R., Lassa, J., Setiamarga, D., Sudjatma, A., Indrawan, M., Haryanti, B., Mahfud, C., Sinapoy, M.S., Djalante, S., Rafliana, I., Gunawan, L.A., Surtiari, G.A.K., & Warsilah, H. (2020). Review and analysis of current responses to COVID-19 in Indonesia: Period of January to March 2020. Progress in Disaster Science, 6, 10091. doi:10.1016/j.pdisas.2020.100091
Doremalen, N.V., Lambe, T., Spencer, A., Belji-Rammerstorfer, S., Purusthotham, J.N., Port, J.R., Avanzato, V., Bushmaker, T., Flaxman, A., Ulaszewska, M., Feldmann, F., Allen, E.R., Sharpe, H., Schulz, J., Holbrook, M., Okumura, A., Meade-White, K., Perez-Perez, L., Bissett, C., Gilbride, C., Williamson, B.N., Rosenke, R., Long, D., Ishwarbhai, A., Kailath, R., Rose, L., Morris, S., Powers, C., Lovaglio, J., Hanley, P.W., Scott, D., Saturday, G., de Wit, E., Gilbert, S.C., & Munster, V.J. (2020). ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. BioRXiv. Preprint, 093195. doi:10.1101/2020.05.13.093195
Duddu, P. (2020). Coronavirus treatment: Vaccines/drugs in the pipeline for COVID-19. https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/
El-Aziz, T.M.A. & Stockand, J.D. (2020). Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status. Infection, Genetics and Evolution, 104327. doi:10.1016/j.meegid.2020.104327
Gautret, P., Lagier, J.C., Parola, P., Hoang, V.T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V.E., Dupont, H.T., Honore, S., Colson, P., Chabriere, E., La Scola, B., Rolain, J.M., Brouqui, P., & Raoult, D. (2020). Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Results of an Open-Label Non-Randomized Clinical Trial. International Journal of Antimicrobial Agents, 105949. doi:10.1016/j.ijantimicag.2020.105949
Guner, R., Hasanoglu, I., & Aktas, F. (2020). COVID-19: Prevention and control measures in community. Turkish Journal of Medical Sciences, 50(3), 571-577. doi:10.3906/sag-2004-146
Guo, Y.R., Cao, Q.D., Hong, Z.S., Tan, Y.Y., Chen S.D., Jin, H.J., Tan, K.S., Wang, D.Y., & Yan, Y. (2020). The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Military Medical Research, 7, 11. doi:10.1186/s40779-020-00240-0
Indian Council of Medical Research. (2020). Total Operational (initiated independent testing) Laboratories reporting to ICMR. https://www.icmr.gov.in/pdf/covid/labs/COVID_19_Testing_Labs_06052020.pdf
Innovation Pharmaceuticals. (2020). Brilacidin. http://www.ipharminc.com/brilacidin-1
Khan, S., Siddique, R., Shereen, M.A., Ali, A., Liu, J., Bai, Q., Bashir, N., & Xue, M. (2020a). Emergence of a Novel Coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2: Biology and Therapeutic Options. Journal of Clinical Microbiology, 58(5), 00187-20. doi:10.1128/JCM.00187-20
Khan, S., Nabi, G., Han, G., Siddique, R., Lian, S., Shi, H., Bashir, N., Ali, A., & Shereen, M.A. (2020b). Novel coronavirus: how things are in Wuhan. Clinical Microbiology and Infection, 26(4), 399-400. doi:10.1016/j.cmi.2020.02.005
Lauer, S.A., Grantz, K.H., Bi, Q., Jones, F.K., Zheng, Q., Meredith, H.R., Azman, A.S., Reich, N.G., & Lessler, J. (2020). The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Annals of Internal Medicine, 172(9), 577-582. doi:10.7326/m20-0504
Li, H., Liu, S.M., Yu, X.H., Tang, S.L., & Tang, C.K. (2020). Coronavirus disease 2019 (COVID-19): current status and future perspectives. International Journal of Antimicrobial Agents, 105951. doi:10.1016/j.ijantimicag.2020.105951
Liu, J., Liao, X., Qian, S., Yuan, J., Wang, F., Liu, Y., Wang, Z., Wang, F.S., Liu, L., & Zhang, Z. (2020a). Community Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, Shenzhen, China, 2020. Emerging Infectius Diseases, 26(6), [Epub ahead of print]. doi:10.3201/eid2606.200239
Liu, J., Cao, R., Xu, M., Wang, X., Zhang, H., Hu, H., Li, Y., Hu, Z., Zhong, W., & Wang, M. (2020b). Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery, 6, 16. doi:10.1038/s41421-020-0156-0
Magro, G. (2020). SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the ‘culprit lesion’ of ARDS onset? What is there besides Tocilizumab? SGP130Fc. Cytokine: X, 2(2), 100029. doi:10.1016/j.cytox.2020.100029
Mantlo, E., Bukreyeva, N., Maruyama, J., Paessler, S., & Huang, C. (2020). Antiviral activities of type I interferons to SARS-CoV-2 infection. Antiviral Research, 179, 104811. doi:10.1016/j.antiviral.2020.104811
Megarbane, B. (2020). Chloroquine and hydroxychloroquine to treat COVID-19: between hope and caution. Clinical Toxicology, 1080(10), 1-3. doi:10.1080/15563650.2020.1748194
Mensa, B., Howell, G.L., Scott, R., & DeGrado, W.F. (2014). Comparative Mechanistic Studies of Brilacidin, Daptomycin, and the Antimicrobial Peptide LL16. Antimicrobial Agents and Chemotherapy, 58(9), 5136-5145. doi:10.1128/AAC.02955-14
Moderna. (2020). Moderna Advances Late-Stage Development of its Vaccine (mRNA-1273) Against COVID-19. https://investors.modernatx.com/news-releases/news-release-details/moderna-advances-late-stage-development-its-vaccine-mrna-1273
Morawska, L. & Cao, J. (2020). Airborne transmission of SARS-CoV-2: the world should face the reality. Environment International, 105730. doi:10.1016/j.envint.2020.105730
Norrie, J.D. (2020). Remdesivir for COVID-19: challenges of underpowered studies. The Lancet, 395(10236), 1525-1527. doi:10.1016/S0140-6736(20)31023-0
Omer, S., Ali, S., & Babar, Z.D. (2020). Preventive measures and management of COVID-19 in pregnancy. Drugs and Therapy Perspectives, 1-4. doi:10.1007/s40267-020-00725-x
Pal, M., Berhanu, G., Desalegn, C., & Kandi, V. (2020). Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update. Cureus, 12(3), e7423. doi:10.7759/cureus.7423
Pawar, A.Y. (2020). Combating Devastating COVID -19 by Drug Repurposing. International Journal if Antimicrobial Agents, 105984. doi:10.1016/j.ijantimicag.2020.105984
Peng, X., Xu, X., Li, Y., Cheng, L., Zhou, X., & Ren, B. (2020). Transmission routes of 2019-nCoV and controls in dental practice. International Journal of Oral Science, 12, 9. doi:10.1038/s41368-020-0075-9
Regeneron Pharmaceuticals. (2020). Corporate Overview. https://investor.regeneron.com/static-files/c1be21c5-bd18-45e4-b8ba-e09e3755fdf5
Rockx, B., Kuiken, T., Herfst, S., Bestebroer, T., Lamers, M.M., Munnink, B.B.O., de Meulder, D., van Amerongen, G., van den Brand, J., Okba, N.M.A., Schipper, D., van Run, P., Leitjen, L., Sikkema, R., Verschoor, E., Verstrepen, B., Bogers, W., Langermans, J., Drosten, C., van Vlissingen, M.F., Fouchier, R., de Swart, R., Koopmans, M., & Haagmans, B.L. (2020). Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science, eabb7314. doi:10.1126/science.abb7314
Sandra, R. (2020). Airway Therapeutics Announces Filing with NIH To Evaluate AT-100 as a Therapy for Novel Coronavirus. https://www.airwaytherapeutics.com/airway-therapeutics-announces-filing-with-nih-to-evaluate-at-100-as-a-therapy-for-novel-coronavirus/
Seah, I., Su, X., & Lingam, G. (2020). Revisiting the dangers of the coronavirus in the ophthalmology practice. Eye, [Epub ahead of print]. doi:10.1038/s41433-020-0790-7
Singhal, T. (2020). A Review of Coronavirus Disease-2019 (COVID-19). Indian Journal of Pediatrics, 8(4), 281-286. doi:10.1007/s12098-020-03263-6
Synairgen Research. (2020). Synairgen to start trial of SNG001 in COVID-19 imminently. https://www.synairgen.com/wp-content/uploads/2020/03/200318-Synairgen-to-start-trial-of-SNG001-in-COVID-19-imminently-.pdf
Takeda. (2020). Rajeev Venkayya, President, Global Vaccine Business Unit on the latest on the Coronavirus and Takeda. https://www.takeda.com/newsroom/featured-topics/rajeev-venkayya-president-global-vaccine-business-unit-on-the-latest-on-the-coronavirus-and-takeda/
Tay, M.Z., Poh, C.M., Renia, L., MacAry, P.A., & Ng, L.F.P. (2020). The trinity of COVID-19: immunity, inflammation and intervention. Nature Reviews Immunology, 1-12. doi:10.1038/s41577-020-0311-8
Tiziana Life Sciences. (2020). Tiziana Lifesciences Develops Novel Investigational Treatment for Patients Infected with COVID-19 Utilizing Direct Delivery of Anti-Interlukin-6-Receptor Monoclonal Antibodies. https://www.globenewswire.com/news-release/2020/04/09/2014044/0/en/Tiziana-Lifesciences-Develops-Novel-Investigational-Treatment-For-Patients-Infected-with-COVID-19-Utilizing-Direct-Delivery-of-Anti-Interlukin-6-Receptor-Monoclonal-Antibodies.html
Tonix Pharmaceuticals. (2020). TNX-1800 (Coronavirus Vaccine). https://www.tonixpharma.com/pipeline/tnx-1800-coronavirus-vaccine
Walls, A.C., Park, Y.J., Tortorici, M.A., Wall, A., McGuire, A.T., & Veesler, D. (2020). Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell, 181(2), 281-292. doi:10.1016/j.cell.2020.02.058
Wang, Q., Zhang, Y., Wu, L., Niu, S., Song, C., Zhang, Z., Lu, G., Qiao, C., Hu, Y., Yuen, K.Y., Wang, Q., Zhou, H., Yang, J., & Qi, J. (2020a). Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell, [Epub ahead of print]. doi:10.1016/j.cell.2020.03.045
Wang, S.X., Wang, Y., Lu, Y.B., Li, J.Y., Song, Y.J., Nyamgerelt, M., & Wang, X.X. (2020b). Diagnosis and treatment of novel coronavirus pneumonia based on the theory of traditional Chinese medicine. Journal of Integrative Medicine, [Epub ahead of print]. doi:10.1016/j.joim.2020.04.001
Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., Hu, Y., Luo, G., Wang, K., Lu, Y., Li, H., Wang, S., Ruan, S., Yang, C., Mei, C., Wang, Y., Ding, D., Wu, F., Tang, X., Ye, X., Ye, Y., Liu, B., Yang, J., Yin, W., Wang, A., Fan, G., Zhou, F., Liu, Z., Gu, X., Xu, J., Shang, L., Zhang, Y., Cao, L., Guo, T., Wan, Y., Qin, H., Jiang, Y., Jaki, T., Hayden, F.G., Horby, P.W., Cao, B., & Wang, C. (2020c). Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet, 395(10236), 1569-1578. doi:10.1016/S0140-6736(20)31022-9
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020d). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research, 30, 269-271. doi:10.1038/s41422-020-0282-0
de Wit, E., Feldmann, F., Okumura, A., Horne, E., Haddock, E., Saturday, G., Scott, D., Erlandson, K.J., Stahl, N., Lipsich, L., Kyratsous, C.A., & Feldmann, H. (2018). Prophylactic and Therapeutic Efficacy of mAb Treatment Against MERS-CoV in Common Marmosets. Antiviral Research, 156, 64-71. doi:10.1016/j.antiviral.2018.06.006
World Health Organization. (2020). DRAFT landscape of COVID-19 candidate vaccines–20 April 2020. https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1
Worldometer. (2020). COVID-19 Coronavirus Pandemic. https://www.worldometers.info/coronavirus/
Xu, J., Zhao, S., Teng, T., Abdalla, A.E., Zhu, W., Xie, L., Wang, Y., & Guo, X. (2020). Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV. Viruses, 12(2), 244. doi:10.3390/v12020244
Yi, Y., Lagniton, P.N.P., Ye, S., Li, E., & Xu, R.H. (2020). COVID-19: what has been learned and to be learned about the novel coronavirus disease. International Journal of Biological Sciences, 16(10), 1753-1766. doi:10.7150/ijbs.45134
Yuen, K.S., Ye, Z.W., Fung, S.Y., Chan, C.P., & Jin, D.Y. (2020). SARS-CoV-2 and COVID-19: The most important research questions. Cell and Bioscience, 10, 40. doi:10.1186/s13578-020-00404-4
Zhai, P., Ding, Y., Wu, X., Long, J., Zhong, Y., & Li, Y. (2020). The epidemiology, diagnosis and treatment of COVID-19. International Journal of Antimicrobial Agents, 105955. doi:10.1016/j.ijantimicag.2020.105955
Zhang, H., Penninger, J.M., Li, Y., Zhong, N., & Slusky, A.S. (2020). Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Medicine, 46(4), 586-590. doi:10.1007/s00134-020-05985-9
Zhou, P., Yang, X., Wang, X. Hu, B., Zhang, L., Zhang, W., Si, H.R., Zhu, Y., Li, B., Huang, C.L., Chen, H.D., Chen, J., Luo, Y., Guo, H., Jiang, R.D., Liu, M.Q., Chen, Y., Shen, X.R., Wang, X., Zheng, X.S., Zhao, K., Chen, Q.J., Deng, F., Liu, L.L., Yan, B., Zhan, F.X., Wang, Y.Y., Xiao, G.F., & Shi., Z.L. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579(7798), 270–273. doi:10.1038/s41586-020-2012-7
Zumla, A., Chan, J.F., Azhar, E.I., Hui, D.S., & Yuen, K.Y. (2016). Coronaviruses - drug discovery and therapeutic options. Nature Reviews Drug Discovery, 15(5), 327-347. doi:10.1038/nrd.2015.37
Authors
1.
Mukim M, Kabra A, Devi S, Chaturvedi M, Patel R. Global Pandemic Conditions and List of Possible Medications and Vaccines for the Treatment of COVID-19: A Review. Borneo J Pharm [Internet]. 2020Jun.22 [cited 2024Dec.22];3(Special-1):90-102. Available from: https://journal.umpr.ac.id/index.php/bjop/article/view/1397
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors continue to retain the copyright to the article if the article is published in the Borneo Journal of Pharmacy. They will also retain the publishing rights to the article without any restrictions.
Authors who publish in this journal agree to the following terms:
- Any article on the copyright is retained by the author(s).
- The author grants the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share work with an acknowledgment of the work authors and initial publications in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of published articles (e.g., post-institutional repository) or publish them in a book, with acknowledgment of their initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their websites) prior to and during the submission process. This can lead to productive exchanges and earlier and greater citations of published work.
- The article and any associated published material are distributed under the Creative Commons Attribution-ShareAlike 4.0 International License.
Article Details
